Tackling antimicrobial resistance in low-income and middle-income countries
Open accessAbstract
Antimicrobial resistance (AMR) is a global threat that claims 700 000 lives every year. If no urgent actions are taken, by 2050, AMR will cause an estimated loss of 10 million lives and $US100 trillion.1 Over the years, commonly identified infectious agents have developed resistance to antimicrobials. Since the discovery of penicillin in 1928, 20 000 potential resistant genes of nearly 400 different types have been identified.2 Methicillin-resistant Staphylococcus aureus alone causes more than 80 000 severe infections and claims more than 11 000 lives each year.3 The World Bank estimates a reduction in global domestic product per annum of 1.1%–3.8% by 2050 if AMR remains unchecked, and that an investment of US$9 billion per year will be required to counteract the problem.4 AMR affects all countries, but the burden is disproportionately higher in low-income and middle-income countries.1 To halt the spread of AMR, it is important to understand what contributes to its emergence. While the overuse of antimicrobials in both humans and animals is broadly implicated and strategies are developed to counteract such an overuse, the broader factors that contribute to AMR are often overlooked. In addition, national action plans on AMR are often constrained by lack of comprehensive multisectoral and multipronged approaches (eg, too focused on the health sector), and their findings are only relevant for a limited period of time as AMR continues to evolve at a fast pace.5 A recent assessment of country situational analyses against the political, economic, sociological, technological, ecological, legislative, and industry (PESTELI) framework identified important gaps in addressing AMR.6 Indeed, collaborative efforts are necessary to delineate global, regional and local contingency plans for AMR. A multitude of factors contribute to the development of AMR. Many of these factors transcend discipline and sectors. Efforts to counteract AMR through a traditional biomedical approach …
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Lower-middle-income countries are the most impacted by AMR.
“Although AMR affects countries across all regions and income levels, lower-middle-income countries are the most impacted [5].”
From A Systematic Review on Antimicrobial Resistance in Ghana from a One Health Perspective (2024) · cites this paper as [5]
The opening section says AMR affects all countries and that its burden is disproportionately higher in low-income and middle-income countries. It does not single out the narrower lower-middle-income group as the most impacted. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 15
- [1]O'Neill J Tackling drug-resistance infections globally: final report and recommendations, 2016 Available: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf [Accessed 8 Jun 2019].
- [2]Davies J, Davies D Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010; 74: 417– 33. 10.1128/MMBR.00016-10 20805405 PMC2937522 · DOI · Paper page
- [5]Kakkar M, Sharma A, Vong S Developing a situation analysis tool to assess containment of antimicrobial resistance in South East Asia. BMJ 2017; 358 10.1136/bmj.j3760 PMC5598290 28874347 · DOI
- [6]Ahmad R, Zhu NJ, Leather AJM, et al Strengthening strategic management approaches to address antimicrobial resistance in global human health: a scoping review. BMJ Glob Health 2019; 4: e001730 10.1136/bmjgh-2019-001730 PMC6747904 31565417 · DOI
- [7]Raut S, Adhikari B Ceftazidime-avibactam in ceftazidime-resistant infections. Lancet Infect Dis 2016; 16: 997 10.1016/S1473-3099(16)30194-3 27684335 · DOI
- [8]Raut S, Adhikari B Global leadership against antimicrobial resistance ought to include developing countries. Lancet Infect Dis 2016; 16: 775 10.1016/S1473-3099(16)30078-0 27352753 · DOI
- [10]Denyer Willis L, Chandler C Quick fix for care, productivity, hygiene and inequality: reframing the entrenched problem of antibiotic overuse. BMJ Glob Health 2019; 4: e001590 10.1136/bmjgh-2019-001590 PMC6703303 31497315 · DOI
- [11]Erasmus V, Daha TJ, Brug H, et al Systematic review of studies on compliance with hand hygiene guidelines in hospital care. Infect Control Hosp Epidemiol 2010; 31: 283– 94. 10.1086/650451 20088678 · DOI
- [13]Bloom G, Merrett GB, Wilkinson A, et al Antimicrobial resistance and universal health coverage. BMJ Glob Health 2017; 2: e000518 10.1136/bmjgh-2017-000518 PMC5717966 29225955 · DOI
- [14]Adhikari B, Phommasone K, Pongvongsa T, et al Treatment-seeking behaviour for febrile illnesses and its implications for malaria control and elimination in Savannakhet Province, Lao PDR (Laos): a mixed method study. BMC Health Serv Res 2019; 19: 252 10.1186/s12913-019-4070-9 31018855 PMC6480816 · DOI
- [16]Huttner B, Saam M, Moja L, et al How to improve antibiotic awareness campaigns: findings of a who global survey. BMJ Glob Health 2019; 4: e001239 10.1136/bmjgh-2018-001239 PMC6528771 31179029 · DOI
- [17]Kleczka B, Kumar P, Njeru MK, et al Using rubber stamps and mobile phones to help understand and change antibiotic prescribing behaviour in private sector primary healthcare clinics in Kenya. BMJ Glob Health 2019; 4: e001422 10.1136/bmjgh-2019-001422 PMC6768358 31637023 · DOI
- [18]Aslam B, Wang W, Arshad MI, et al Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist 2018; 11: 1645– 58. 10.2147/IDR.S173867 30349322 PMC6188119 · DOI
- [19]Hampton LM, Farley MM, Schaffner W, et al Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2012; 205: 401– 11. 10.1093/infdis/jir755 22158567 · DOI
- [22]Wernli D, Jørgensen PS, Morel CM, et al Mapping global policy discourse on antimicrobial resistance. BMJ Glob Health 2017; 2: e000378 10.1136/bmjgh-2017-000378 PMC5717922 29225939 · DOI
Cited by
Sorted by citations
Sono, T. M., Yeika, E., Cook, A., Kalungia, A., Opanga, S. A., Acolatse, J. E. E., Sefah, I. A., Jelić, A. G., Campbell, S., Lorenzetti, G., et al. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2259106 · Cited by 95 · see citing works
Antibiotic Usage and Resistance in Food Animal Production: What Have We Learned from Bangladesh?
Chowdhury, S., Ghosh, S., Aleem, M. A., Parveen, S., Islam, M. A., Rashid, M. M., Akhtar, Z., & Chowdhury, F. (2021) · Antibiotics · doi:10.3390/antibiotics10091032 · Cited by 70 · see citing works
A Systematic Review on Antimicrobial Resistance in Ghana from a One Health Perspective
Donkor, E. S., Odoom, A., Osman, A.-H., Darkwah, S., & Kotey, F. C. N. (2024) · Antibiotics · doi:10.3390/antibiotics13070662 · Cited by 52 · see citing works
“Although AMR affects countries across all regions and income levels, lower-middle-income countries are the most impacted [5].”
BackgroundAssessment of rationality of available fixed dose combinations of antibiotics in India
Anand, P., Kaur, N., Verma, V., Shafiq, N., & Malhotra, S. (2022) · Expert Review of Anti-Infective Therapy · doi:10.1080/14787210.2022.2015324 · Cited by 10 · see citing works
- Authors
- Pokharel, S., Raut, S., & Adhikari, B.
- Affiliations
- University of Oxford (GB)
- Universal College of Medical Sciences (NP)
- Corresponding author
- Adhikari, Bipin
- Venue
- BMJ Global Health
- Publisher
- BMJ
- Published
- 2019-11
- Volume
- 4
- Issue
- 6
- Pages
- e002104
- ISSN
- 2059-7908 (ISSN-L)
- PMC
- PMC6861125
- OpenAlex
- W2984919370
- Cited by
- 407
- References
- 0
- Citations by year
- 2026: 50 · 2025: 60 · 2024: 99 · 2023: 60 · 2022: 60 · 2021: 47 · 2020: 28 · 2019: 3
- FWCI
- 22.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Global Health (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antibiotic Use and Resistance
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- antimicrobial resistance, low- and middle-income countries, national action plans, antimicrobial overuse, multisectoral approach, methicillin-resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review